Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
ISRCTN | ISRCTN74348595 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN74348595 |
ClinicalTrials.gov number | NCT00124072 |
Secondary identifying numbers | CTSU SEARCH1 |
- Submission date
- 15/08/2005
- Registration date
- 09/09/2005
- Last edited
- 31/08/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English Summary
Not provided at time of registration
Contact information
Prof Rory Collins
Scientific
Scientific
Clinical Trial Service Unit
Richard Doll Building
Old Road Campus
Oxford
OX3 7LF
United Kingdom
Phone | +44 (0)1865 743743 |
---|---|
Secretary@ctsu.ox.ac.uk |
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Scientific title | Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine |
Study acronym | SEARCH |
Study hypothesis | Do larger reductions in blood cholesterol produce larger, and worthwhile, reductions in cardiovascular risk, and does homocysteine-lowering with folic acid and vitamin B12 reduce cardiovascular risk? |
Ethics approval(s) | Not provided at time of registration |
Condition | Coronary heart disease |
Intervention | Simvastatin 80 mg versus 20 mg daily, and separately folic acid 2 mg plus 1 mg vitamin B12 daily or matching placebo tablets. |
Intervention type | Supplement |
Primary outcome measure | Major vascular events (MVEs) during the scheduled treatment period |
Secondary outcome measures | MVEs separately during the first year and in the later years of the study, MVEs in patients subdivided by pre-randomisation lipid levels, MVEs in the presence and absence of the other randomised treatments, major coronary events, total strokes |
Overall study start date | 30/07/1998 |
Overall study end date | 31/12/2007 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 12,064 |
Total final enrolment | 12064 |
Participant inclusion criteria | Men and women who have survivied a heart attack and in whom statin therapy is indicated. |
Participant exclusion criteria | Age under 18 years or over 80 at invitation, contraindications to either study drug, other predominant medical problem. |
Recruitment start date | 30/07/1998 |
Recruitment end date | 31/12/2007 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Clinical Trial Service Unit
Oxford
OX3 7LF
United Kingdom
OX3 7LF
United Kingdom
Sponsor information
University of Oxford (UK)
University/education
University/education
University Offices
Wellington Square
Oxford
OX1 2JD
England
United Kingdom
Phone | +44 (0)1865 270000 |
---|---|
search@ctsu.ox.ac.uk | |
Website | http://www.ox.ac.uk |
https://ror.org/052gg0110 |
Funders
Funder type
Industry
A grant to Oxford University from Merck and Co.
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan | Not provided at time of registration |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 21/08/2008 | Yes | No | |
Results article | results | 23/06/2010 | Yes | No | |
Basic results | 26/09/2019 | No | No |
Editorial Notes
31/08/2022: A long-term follow-up study of SEARCH has been registered as ISRCTN14416153.
26/09/2019: The following changes were made to the trial record:
1. Added ClinicalTrials.gov link to basic results (scientific).
2. The total final enrollment was added.
3. ClinicalTrials.gov number added.